Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist.
Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist.
复制标题
DOI：
10.1016/j.ejphar.2010.10.085
复制
发表时间：
2011-01-25
影响因子：
5
通讯作者：
Martin, Billy R.
中科院分区：
文献类型：
--
作者：
Wiley, Jenny L.;Breivogel, Christopher S.;Mahadevan, Anu;Pertwee, Roger G.;Cascio, Maria Grazia;Bolognini, Daniele;Huffman, John W.;Walentiny, D. Matthew;Vann, Robert E.;Razdan, Raj K.;Martin, Billy R.
Rimonabant, the prototypic antagonist of cannabinoid CB1 receptors, has been reported to have inverse agonist properties at higher concentrations, which may complicate its use as a tool for mechanistic evaluation of cannabinoid pharmacology. Consequently, recent synthesis efforts have concentrated on discovery of a neutral antagonist using a variety of structural templates. The purpose of this study was to evaluate the pharmacological properties of the putative neutral cannabinoid CB1 receptor antagonist O-2050, a sulfonamide side chain analog of Δ8-tetrahydrocannabinol. O-2050 and related sulfonamide cannabinoids exhibited good affinity for both cannabinoid CB1 and CB2 receptors. While the other sulfonamide analogs produced cannabinoid agonist effects in vivo (e.g., activity suppression, antinociception, and hypothermia), O-2050 stimulated activity and was inactive in the other two tests. O-2050 also decreased food intake in mice, an effect that was reminiscent of that produced by rimonabant. Unlike rimonabant, however, O-2050 did not block the effects of cannabinoid agonists in vivo, even when administered i.c.v. In contrast, O-2050 antagonized the in vitro effects of cannabinoid agonists in [35S]GTPγS and mouse vas deferens assays without having activity on its own in either assay. Further evaluation revealed that O-2050 fully and dose-dependently substituted for Δ9-tetrahydrocannabinol in a mouse drug discrimination procedure (a cannabinoid agonist effect) and that it inhibited forskolin-stimulated cyclic AMP signaling with a maximum efficacy of approximately half that of the full agonist CP55,940 [(−)-cis-3-[2-hydroxy-4(1,1-dimethyl-heptyl)phenyl]-trans-4-(3-hydroxy-propyl)cyclohexanol]. Together, these results suggest that O-2050 is not a viable candidate for classification as a neutral cannabinoid CB1 receptor antagonist.
登录
查看更多内容
影响因子：
3.5
作者：
Higuchi, Sei;Irie, Keiichi;Fujiwara, Michihiro
通讯作者：
Fujiwara, Michihiro
影响因子：
5
作者：
Pertwee, RG;Fernando, SR;Martin, BR
通讯作者：
Martin, BR
影响因子：
5
作者：
Gardner, A;Mallet, PE
通讯作者：
Mallet, PE
影响因子：
3.4
作者：
Järbe, TUC;Liu, QA;Makriyannis, A
通讯作者：
Makriyannis, A
影响因子：
7.3
作者：
Griffin, G;Wray, EJ;Abood, ME
通讯作者：
Abood, ME